Observed Signal · Nov 5, 2026 · Funding · Source: Trending Topics (DACH/CEE Innovation & Tech) · Impact: 4/5 · Sentiment: Positive
Isomorphic Labs seeks $5B round at $50B valuation
Isomorphic Labs, Alphabet's AI drug discovery spinout led by Demis Hassabis, is reportedly in early-stage talks to raise approximately $5 billion at a valuation of around $50 billion, according to Bloomberg. This round would follow a $2.1 billion Series B in May and a $600 million round in 2025, bringing total raised to nearly $7.7 billion within 18 months. Despite the massive funding, the company has not yet tested any drug candidate in humans; clinical trials were initially planned for end of 2025, then delayed to late 2026. Investors are valuing the platform rather than a product, a record for a pre-clinical biotech. Revenue currently comes from partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with milestone-based payments potentially reaching up to $2.9 billion. Skepticism remains, as Eli Lilly's CEO Dave Ricks has questioned the effectiveness of AI in drug discovery, noting that protein structure prediction is just one part of the challenge.
This news is highly significant for the AI and biotech sectors, highlighting the massive capital influx into AI-driven drug discovery. It underscores the potential of AI in transforming pharmaceutical R&D, despite the lack of clinical validation. The valuation and funding amount are unprecedented for an AI biotech with no human trials, influencing investor sentiment and industry benchmarks.
Track Alphabet Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Isomorphic Labs is in early talks to raise about $5 billion at a valuation of about $50 billion.
- The company has not yet tested any drug candidate in humans; clinical trials were postponed to end of 2026.
- The $5 billion round would follow a $2.1 billion Series B in May 2026 and a $600 million round in 2025.
- Revenue comes from partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with milestone payments potentially up to $2.9 billion.
- Alphabet holds a stake in Isomorphic Labs that would be worth more on paper if the round closes at $50 billion valuation.
Connected Companies & Entities
9 Entities mapped“Parent company of Google DeepMind and holds a stake in Isomorphic Labs.”
“AI research lab from which Isomorphic Labs was spun out.”
“Partner with milestone payments up to $1.7 billion.”
“Led the previous funding rounds.”
“Partner of Isomorphic Labs.”
“Growth fund of Alphabet, participated in previous rounds.”
“Investor in Isomorphic Labs.”
“Investor in Isomorphic Labs.”
“Venture capital arm of Alphabet, participated in previous rounds.”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Modal Labs Eyes $2.5B Valuation Amid Funding Talks
Modal Labs, an AI inference infrastructure startup, is in early talks with venture capital firms to raise a financing round valuing the company at about $2.5 billion, according to multiple sources. If completed at those terms, the round would more than double Modal’s valuation from the $1.1 billion announced under an $87 million Series B less than five months earlier. General Catalyst is reported to be in discussions to lead the round. Sources told TechCrunch Modal has an approximate $50 million annualized revenue run rate (ARR). CEO and co-founder Erik Bernhardsson denied an active fundraising process, calling recent VC contact general conversations. The story situates Modal among several inference-focused companies drawing large rounds and valuations, citing competitor financings from Baseten, Fireworks AI, Inferact (vLLM creators) and RadixArk. Modal’s earlier investors include Lux Capital and Redpoint Ventures.
UK Sovereign AI Fund and Stripe CEO Back Potential Sciences
London-based startup Potential Sciences has raised a multi-million-dollar seed round backed by the UK government's Sovereign AI fund and Stripe CEO Patrick Collison. The company is developing AI infrastructure for scientific drug discovery, using AI, machine learning, and quantum chemistry simulations to model molecular behavior. Its physics-based AI approach aims to reduce the cost of chemical design calculations by up to 100 times. The Sovereign AI fund is also providing compute capacity. Other investors include Twin Path Ventures, Odyssey, Portfolio Ventures, Blue Wire Capital, rule30, Nauta Capital, and Lightfield Equity. The company declined to disclose the exact amount raised or its valuation. Potential Sciences was founded in November 2025 by Hatem Helal, a former Graphcore executive.
Cognition in talks to raise at $40B valuation
Cognition, maker of the AI coding agent Devin, is reportedly in early investor talks for a funding round that could value the company at about $40 billion, contingent on reaching an asserted $1 billion annualized revenue run rate. The company raised $1 billion in May at roughly a $26 billion valuation and three months later reported a $492 million ARR and Devin enterprise usage growing about 50% month‑over‑month over six months. Cognition’s customers include Mercedes‑Benz, NASA and Goldman Sachs. It acquired AI coding startup Windsurf in July 2025 amid reports of a tentative, vetoed $3 billion acquisition attempt involving OpenAI and Microsoft. The fundraising news appears amid broader AI tooling consolidation — Cursor joining SpaceXAI, a blocked Meta deal for Manus AI, and reports of Stripe nearing OpenRouter.
Receive all future signals for Alphabet & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.